Skip to content
akaturk Academic measurement
Sign in Sign up

OpenAlex topic

Hepatocellular Carcinoma Treatment and Prognosis

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 3,715 works 145 author topics

Works

3,715 works

  1. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma 2018
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced disease. This randomized,…

  2. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates 2018
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  3. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study 2020
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    BACKGROUND: The burden of non-alcoholic fatty liver disease (NAFLD) is increasing globally, and a major priority is to identify patients with non-alcoholic steatohepatitis (NASH) who are at greater risk of progression to cirrhosis, and who will be candidates for clinical trials and emerging new pharmacotherapies. We a…

  4. The International Association for the Study of Lung Cancer Lung Cancer Staging Project Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer 2015
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    No abstract yet.

  5. Minimally Invasive Treatment of Malignant Hepatic Tumors: At the Threshold of a Major Breakthrough 2000
    YÖKSİS SJR Q1 JCR Q2 OpenAlex top 1% OpenAlex 99.7%

    Six existing minimally invasive techniques for the treatment of primary and secondary malignant hepatic tumors--radio-frequency ablation, microwave ablation, laser ablation, cryoablation, ethanol ablation, and chemoembolization--are reviewed and debated by noted authorities from six institutions from around the world.…

  6. PAGE B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5 year antiviral therapy 2016
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.4%

    No abstract yet.

  7. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy 2016
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.4%

    No abstract yet.

  8. Page B Risk Score for Hepatocellular Carcinoma in Caucasians with Chronic Hepatitis B Under 5 Year Entecavir or Tenofovir Therapy 2015
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.4%

    No abstract yet.

  9. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence 2016
    YÖKSİS SJR Q2 JCR Q2 OpenAlex top 1% OpenAlex 99.4%

    No abstract yet.

  10. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis 2022
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    OBJECTIVE: Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFL…

  11. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial 2023
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  12. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial 2023
    OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

Academicians

145 academicians